September 9, 2025

Positrigo, a Swiss based company developing nuclear medical imaging devices to advance functional brain imaging, today announced two key leadership appointments to support its accelerating commercial growth. Jerome Descheirder joins as Chief Commercial Officer (CCO), and Dr. Stefan Bircher transitions into the newly created role of Chief Business Development and Marketing Officer (CBDMO).

Jerome Descheirder brings over two decades of experience in the healthcare sector, having spent most of his career at GE HealthCare in various global leadership roles across sales, marketing, and operations. In recent years, he served as a partner to a leading venture capital firm, supporting the growth of health tech startups. As CCO, Jerome will lead Positrigo’s global commercial strategy, with a focus on scaling sales and expanding into new markets.

“I am thrilled to welcome Jerome to the Positrigo team at this pivotal moment,” states Dr. Jannis Fischer, CEO and Co-founder of Positrigo. “We are entering a phase of strong commercial traction, and Jerome’s deep industry expertise and strategic vision will be critical in driving our next stage of growth.”

Alongside this appointment, Stefan Bircher, who has been instrumental in building Positrigo’s go-to-market function, will assume the newly defined role of CBDMO. In this capacity, Stefan will focus on shaping Positrigo’s marketing strategy, partnerships, and long-term business development initiatives.

“With Jerome’s arrival and Stefan’s expanded role, we are strengthening our commercial leadership to match the growing momentum behind our technology,” added Fischer.

These leadership changes come as Positrigo continues to advance its flagship product, NeuroLF, a compact and cost-efficient PET brain imaging system, aimed at expanding access to high-quality neuroimaging worldwide.